Showing 64,901 - 64,920 results of 65,898 for search '(( 5 ((we decrease) OR (a decrease)) ) OR ( 5 ((nn decrease) OR (mean decrease)) ))', query time: 1.14s Refine Results
  1. 64901

    Table_2_Dietary Supplementation of Ferrous Glycine Chelate Improves Growth Performance of Piglets by Enhancing Serum Immune Antioxidant Properties, Modulating Microbial Structure a... by Jiayu Ma (7518203)

    Published 2022
    “…<p>The present research aimed to explore the effect of dietary ferrous glycine chelate supplementation on performance, serum immune-antioxidant parameters, fecal volatile fatty acids, and microbiota in weaned piglets. A total of 80 healthy piglets (weaned at 28 day with an initial weight of 7.43 ± 1.51 kg) were separated into two treatments with five replicates of eight pigs each following a completely randomized block design. …”
  2. 64902
  3. 64903

    Table_1_Evolving Therapy for Celiac Disease.docx by Shakira Yoosuf (6695333)

    Published 2019
    “…Based on their mechanisms of action on various molecular targets involved in the pathogenesis of CeD, these therapies may be classified into one of the following five broad approaches. The first approach focuses on decreasing the immunogenic content of gluten, using strategies like genetically modified wheat, intra-intestinal gluten digestion using glutenases, microwave thermal treatment of hydrated wheat kernels, and gluten pretreatment with either bacterial/ fungal derived endopeptidases or microbial transglutaminase. …”
  4. 64904
  5. 64905
  6. 64906
  7. 64907
  8. 64908
  9. 64909
  10. 64910
  11. 64911
  12. 64912
  13. 64913
  14. 64914
  15. 64915

    Data_Sheet_1_Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients.docx by Lidan Yang (6918764)

    Published 2022
    “…Objective<p>Metabolic associated fatty liver disease (MAFLD) affects nearly a quarter of the world’s population. Our study aimed to characterize the gut microbiome and overall changes in the fecal and serum metabolomes in MAFLD patients.…”
  16. 64916
  17. 64917
  18. 64918
  19. 64919
  20. 64920